Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

NCT00413686

Solid Tumors

COMPLETED PHASE1

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

NCT00613652

Cancer Tumors Carcinoma

COMPLETED PHASE1

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

NCT03980821

Advanced Solid Malignancies

COMPLETED PHASE1

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

NCT00473616

Advanced Solid Tumors Cancer Advanced Solid Malignancies

TERMINATED PHASE1

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

NCT01353781

Advanced Solid Malignancy Advanced Solid Tumor

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Solid Tumors Advanced Solid Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AZD7762 + gemcitabine

AZD7762 administered alone and in combination with gemcitabine

Group Type OTHER

AZD7762

Intervention Type DRUG

solution, intravenous, weekly

gemcitabine

Intervention Type DRUG

intravenous, weekly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD7762

solution, intravenous, weekly

Intervention Type DRUG

gemcitabine

intravenous, weekly

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Gemzar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Japanese patients with advanced solid tumors for which standard treatment does not exist or is no longer effective.
* Must be suitable for treatment with gemcitabine
* Relatively good overall health other than cancer